Get access

Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?

Authors


  • Sternberk Hospital, Sternberk (D. Stejskal), University of Veterinary and Pharmaceutical Sciences, Brno (M. Karpisek), Czech Republic.

David Stejskal, MD, PhD, Department of Laboratory Medicine, Sternberk Hospital, Jivavska 20, 78516 Sternberk, Czech Republic. Tel.: +42 0585087308; fax: +42 0585087131; e-mail: david.stejskal@quick.cz

Abstract

Background  Adipocyte fatty acid binding protein (A-FABP) has been suggested as playing an important role in the pathogenesis of metabolic syndrome. The aim of this study was to evaluate serum A-FABP as a marker of metabolic syndrome and to assess its predictive accuracy in a Caucasian population.

Materials and methods  Anthropometric and serum analyses were performed for body mass index (BMI), waist circumference, A-FABP, insulin, triglycerides, total cholesterol, high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), uric acid, and glucose on 67 non-obese, healthy subjects and 71 subjects with metabolic syndrome. Quicki-quantitative insulin sensitivity check index, receiver operating characteristic curve (ROC-curve) and χ2 analysis were completed.

Results  Compared with healthy controls, subjects with metabolic syndrome had a significantly higher A-FABP serum level (mean: 42·4 vs. 23·7 µg L−1; P < 0·01). The A-FABP serum level correlated with fasting levels of insulin (r = 0·34; P < 0·01), glucose (r = 0·21; P = 0·01), triglycerides (r = 0·4; P < 0·01), BMI (r = 0·57; P < 0·01) and waist circumference (r = 0·51; P < 0·01), but negatively with HDL-c (r = –0·23; P < 0·01) and Quicki (r = –0·32; P < 0·01). The relationship was defined between serum A-FABP level and metabolic syndrome diagnosis with 40% sensitivity and 99% specificity at A-FABP level 16·4 µg L−1.

Conclusions  Serum A-FABP level might be an independent marker of metabolic syndrome in a Caucasian population.

Ancillary